JHU (Baltimore)

The Clinical Research Site at Johns Hopkins, directed by Sonya Krishnan, MD, occupies space on  the East Baltimore Medical Campus. The JHU CRS takes advantage of the many units available within Johns Hopkins Hospital, including Inpatient/Overnight Services for adult research participants, the Outpatient Research Unit, Inpatient/Outpatient Service for pediatric research participants, research nutrition services, and the Drug Development and Analysis Unit.

The HIV Care Program serves as the most important resource for patient referrals to ACTG clinical trials and is also an important referral source for HPTN trials. The Service was founded in 1983, and the principal components are summarized below:

Laboratory Facilities
All sample processing for virology assays for the CRS will be performed in the HIV Specialty Lab and includes a tissue culture room, specimen prep room, a PCR amplification room, a room for HIV antibody testing and a PCR detection room. The HIV/STD Research Laboratory is recognized internationally for expertise as a reference laboratory for all STDs, especially gonorrhea and chlamydia testing. Both the gonococcal and chlamydial sections of this laboratory are licensed by the State of Maryland and Clinical Laboratory Improvement Amendments (CLIA; ID # 21D0680509; State of Maryland laboratory permit #008 and 940247, respectively) for STD diagnostic evaluations, and are recognized as leading diagnostic labs in the United States.

Clinical Trials

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More

A5282: A Randomized, Phase II Trial to Compare an HPV...

The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More